Evidence map›Paper›PMID 28359247›Full record

ArticleCurrent cancer drug targets2017

Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.

Liang Zhao, Jessie L-S Au, M Guillaume Wientjes

Abstract read
In one paragraph

Article in Current cancer drug targets, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Pharmacodynamic Drug-Drug Interactions.Clinical pharmacology and therapeutics · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Liang ZhaoThe Ohio State University, Columbus, OH. United States.
Jessie L-S AuThe Ohio State University, Columbus, OH. United States.
M Guillaume WientjesOptimum Therapeutics, LLC, 1815 Aston Ave STE 107, Carlsbad, CA 92008. United States.
The Ohio State University · USOptimum Therapeutics (United States) · US

Funding

Targeting multiple signaling steps to achieve synergyR01CA163015 · NCI · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2012 to 2017
$1.9M
Synergistic chemo-siRNA combination therapyR01CA158300 · NCI · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2011 to 2015
$1.8M
Multiscale computational models for developing combination cancer therapyR01GM100487 · NIGMS · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2011 to 2014
$1.3M
NCI NIH HHS R01 CA158300NCI NIH HHS R01 CA163015NIGMS NIH HHS R01 GM100487
6 · The paper itself

Abstract

backgroundCommonly used methods for analyzing interactivity between drugs (e.g. synergy, antagonism) such as isobologram, combination index, and curve shift are based on the Loewe Additivity principle of dose equivalence and the inherent assumption of similar concentration- effect (C-E) including parallel curves and equal maximum effects (Emax), and therefore are not suitable for drugs with dissimilar C-E. This study describes a new method that is without this limitation and has the additional advantage of enabling statistical analysis. METHODS AND

resultsThe method comprises two steps. First, based on the dose equivalence principle, the experimentally obtained C-E of one drug was used to calculate the equally effective C-E of the other drug at no interactivity; the resulting two zero-interactivity C-E formed the upper and lower boundaries of Additivity Envelope. Next, 95% confidence intervals calculated from experimental data were added to Additivity Envelope to obtain Uncertainty Envelope (UE). Experimentally observed effects of drug combinations (C-Ecomb,observed) located within UE indicate additivity whereas C-Ecomb,observed located above or below UE indicate statistically significant (p<0.05) synergy or antagonism, respectively. Additional in silico studies demonstrated the shape and size of Additivity Envelope, which determines the ability to detect drug interactivity, depended on the Drug A-to-B concentration ratios and the ratios of their C-E curve shape parameter. Analyses of experimental results of combinations of drugs with nonparallel C-E and/or unequal Emax indicated UE as more versatile and provided more information, compared to earlier methods.

conclusionUE is a broadly applicable method for analysis, including statistical significance assessment, of drug interactivity.

Indexed as

Drug InteractionsCell Line, TumorComputer SimulationDose-Response Relationship, DrugHumansPharmaceutical PreparationsPharmaceutical PreparationsantagonismCombination therapydrug-drug interactivityloewe-additivitystatistically significant synergyuncertainty envelope

Identifiers

PMID28359247
PMCPMC5623138
OpenAlexW2602287372

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.